Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Retrospect Stage IND EXEMPT Clinical Study - Etoposide and Single Nucleotide Polymorphisms (Drugs-SNPs)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Dr. Han Xu, President/CEO / PD / PI / Monitor / IRB Chair, Medicine Invention Design, Inc
ClinicalTrials.gov Identifier:
NCT01064466
First received: February 2, 2010
Last updated: July 13, 2014
Last verified: July 2014